Diffusion Capital Partners
Mikro Biyosistemler Elektronik’s lab-on-a-chip approach detects multiple drug resistance based on electrical signals. The success of treatment in cancer is highly dependent on the early detection and selection of the most appropriate route of therapy at the beginning of the disease. Development of multiple drug resistance (MDR) is one of the main reasons of recurrence and high mortality in cancer. Currently, there is no low-cost rapid detection system to be used in clinics in routine analysis. Mikro Biyosistemler Inc. aims to develop a modular, simple to operate, low-cost microfluidic platform for rapid and high throughput identification of MDR for cancer. The system will create a breakthrough in cancer diagnosis and prognosis, helping the physicians guide the chemotherapy in early stages of the disease, and hence reduce the treatment period and increase the success rate, considerably.